Investment Rationale & Financial Strength - The company is an industry leader in rapid point-of-care infectious disease testing and DNA/RNA sample self-collection, stabilization, and preparation products[5] - The company has a strong balance sheet with over $178 million in cash and investments, no debt, and sustainable profitability[5, 63] Molecular Solutions Growth - Molecular solutions are experiencing growth from existing customers and increased demand from emerging genetic testing offerings and large studies[19] - In November 2017, the company announced a $143 million supply agreement for OrageneDx to a leading consumer genomics customer, over several years, with minimum annual purchase requirements[24] - The company's products drive scalability and access to donors in human genome testing[27] Infectious Disease Solutions & Market Opportunities - Approximately 36.7 million people are living with HIV, and there were 1.8 million new infections in 2016[46] - An estimated 71 million people globally have chronic hepatitis C infection, with approximately 399,000 deaths each year from HCV[56] - The company was awarded a $10.4 million BARDA contract for Ebola and $16.6 million BARDA contract for Zika[60, 61]

Financial Performance & Guidance - Q1 revenue reached $30.1 million, exceeding consensus estimates[10] - Q2 revenue guidance is projected between $40.0 million and $42.0 million, with net income of approximately $0.02 per share[11] - Full-year revenue guidance is set at $170 million to $175 million, with net income between $0.22 and $0.24 per share[11] - The company held $183.6 million in cash and investments as of March 31, 2019[11] Market Growth - Microbiome market revenue increased by 83% compared to Q1 2018[11] - Genomics sales in Asia increased by 231% compared to Q1 2018[11] - Domestic HCV revenues increased by 12% compared to Q1 2018[11] - International HCV sales increased by 119% compared to Q1 2018, primarily in Asia and Eastern Europe[11] Strategic Focus - The company is an industry leader in DNA/RNA sample self-collection, stabilization, and preparation products, as well as rapid point-of-care infectious disease testing[8] - The company is expanding further in established markets with strong demand for OraQuick HIV Self Test and OraQuick HCV test[8]

"Our Q1 results were consistent with our expectations. Our customers continue to demonstrate their preference for our differentiated products in delivering on their important health objectives, even while uncertainty remains elevated related to government funding sources for some segments," said OraSure President and CEO Carrie Eglinton Manner. "We are making good progress in advancing our innovation roadmap, including multiple new product milestones planned in 2025, and OTI is positioned to deliver acceler ...